Integer (NYSE:ITGR – Get Free Report) and CVRx (NASDAQ:CVRX – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.
Analyst Ratings
This is a summary of current ratings for Integer and CVRx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integer | 1 | 6 | 4 | 0 | 2.27 |
| CVRx | 1 | 0 | 1 | 2 | 3.00 |
Integer currently has a consensus price target of $98.71, indicating a potential upside of 10.23%. CVRx has a consensus price target of $11.50, indicating a potential upside of 106.09%. Given CVRx’s stronger consensus rating and higher probable upside, analysts plainly believe CVRx is more favorable than Integer.
Insider and Institutional Ownership
Earnings & Valuation
This table compares Integer and CVRx”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integer | $1.86 billion | 1.64 | $102.81 million | $4.01 | 22.33 |
| CVRx | $56.65 million | 2.61 | -$53.31 million | ($2.02) | -2.76 |
Integer has higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Integer and CVRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integer | 7.64% | 12.83% | 6.51% |
| CVRx | -89.14% | -120.76% | -48.38% |
Volatility and Risk
Integer has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, CVRx has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Summary
Integer beats CVRx on 9 of the 15 factors compared between the two stocks.
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
About CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.
